Dr. Gruia-Gray joined ESA Biosciences in December 2007 as vice president of marketing for the life sciences area. She now oversees Magellan’s life sciences tools business, comprising novel HPLC detection systems, including the Corona® CAD® charged aerosol detector and electrochemical-detection products sold under the ESA brand name, designed to improve results for pharmaceutical development and QA/QC, life science, and analytical-chemistry customers worldwide. Dr. Gruia-Gray came to Magellan after a 10-year career at Amersham Biosciences, now GE Healthcare, where she was most recently director of marketing for the company’s protein sciences/protein characterization business. When Dr. Gruia-Gray started at Amersham, she worked with customers to troubleshoot their product and applications problems as a technical-support specialist in molecular biology. She advanced rapidly to become a product manager for specialty bioproducts. From 2000 to 2004, Dr. Gruia-Gray served as Amersham’s director of marketing for proteomics. Under her leadership, the company’s proteomics portfolio of hardware, software, and reagents products experienced double-digit growth. Before joining Amersham, she was science coordinator and research scientist at the New York University Medical Center/Salk School of Science, a collaboration between NYU and the New York City Department of Education that offers a science-enrichment curricula to New York middle school students. Dr. Gruia-Gray holds a PhD in molecular biology from the University of Toronto.
|
